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3148Objective: Ventilator-associated pneumonia (VAP) is the most common and serious nosocomial infection that
threatens patients who have undergone cardiac surgery. This article summarizes its clinical characteristics and
provides theoretical evidence for prevention and treatment.
Methods: A literature search was conducted using PubMed, Embase, the Cochrane Library, and Web of
Knowledge databases and by manual search. Data involving the prevalence, etiology, risk factors, or clinical
outcomes were extracted for systematic review and meta-analysis.
Results: Eleven studies on VAP after cardiac surgery were included.When the results were merged the VAP rate
was 21.27/1000 ventilator-days. The prevalence reached 6.37% of all patients and 35.2% of patients who were
on mechanical ventilation for more than 48 hours. Among the isolated pathogens, Pseudomonas aeruginosa
had the highest detection rate, with an average of 23.19%, followed by Staphylococcus aureus (20.15%),
Haemophilus influenzae (19.53%), Acinetobacter baumannii (10.68%), Escherichia coli (10.18%), Klebsiella
pneumoniae (9.52%), andCandida albicans (7.20%). Risk factors were also analyzed.We found that NewYork
Heart Association cardiac function class IV, pulmonary hypertension, chronic obstructive pulmonary disease,
peripheral vascular disease, renal disease, emergency surgery, intra-aortic balloon counterpulsation, cardiopul-
monary bypass time, aortic crossclamp time, mechanical ventilation time, reintervention, and reintubation were
closely related to the occurrence of VAP; there was no association with gender and diabetes mellitus. Once
patients had VAP, mortality and length of stay in the intensive care unit were significantly increased.
Conclusions: VAP in patients after cardiac surgery is common and has a poor prognosis. It is mainly caused by
gram-negative bacteria, and could be affected by a series of factors. (J ThoracCardiovasc Surg 2014;148:3148-55)See related commentary on pages 3155-6.Supplemental material is available online.Ventilator-associated pneumonia (VAP), defined as pulmo-
nary infection developing 48 hours or more after initiation
of mechanical ventilation, is one of the most common
nosocomial infections in critically ill patients.1 It is reported
that VAP is responsible for a significant increase in
mortality and morbidity, and is associated with the highest
costs resulting from prolonged hospitalization, pharmaco-
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The Journal of Thoracic and Cardiovascular SurOnce patients need intubation or ventilator support, the
risk of VAP is increased 7- to 21-fold.4 Patients who have
undergone cardiac surgery and a stay in the intensive care
unit (ICU) usually need long-time mechanical ventilation;
they represent a special subpopulation at high risk for
VAP.5 However, limited information exists regarding the
clinical characteristics of VAP in this setting, and
most studies were carried out in a single institution. The
incidence of VAP reported in these studies varies widely.
Several studies describe the pathogenic microorganisms,
but the conclusions remain controversial. In addition, there
is no consensus on what contributes to the occurrence of
postoperative VAP. Therefore, a detailed, systematic, and
comprehensive summary is urgently needed.
In the present study, we selected eligible studies related
to VAP in all populations undergoing cardiac surgery, and
then performed a systematic review and meta-analysis of
its prevalence, etiology, risk factors, and clinical outcomes.
Our objective was to provide clinical evidence for the
prevention and treatment of VAP after cardiac surgery.METHODS
Search Strategy
A literature search was conducted using PubMed, the Excerpta Medica
database (Embase), and the Cochrane Library and Web of Knowledge
databases up to October 2013. No language or country restrictions weregery c December 2014
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Mapplied. We used exploded Medical Subject Headings and appropriate
corresponding terms as follows: (‘‘ventilator associated pneumonia’’ OR
‘‘nosocomial pneumonia’’) AND (‘‘cardiac’’ OR ‘‘heart’’ OR ‘‘cardiopul-
monary bypass’’ OR ‘‘extracorporeal circulation’’). Reference lists of
published studies were also manually searched for further relevant studies.
Our search strategy was in accordance with the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analysis) guidelines.6
Inclusion Criteria and Study Selection
Studies included in the present analysis met the following inclusion
criteria: (1) a clear definition and diagnosis of VAP was included; (2) all
enrolled patients had undergone heart operations; (3) articles must provide
1 or more index for the prevalence, etiology, risk factors, or clinical
outcomes of VAP; (4) a corresponding comparison group was used;
(5) when multiple publications seemed to contain duplicate results, the
study with the largest population was included. An article was excluded
if it did not fulfill all of these criteria. Reviews and repeated literature
were also excluded. Potential eligible articles were screened by 2 reviewers
(S.H. and Y.X.) independently and in duplicate according to the inclusion
and exclusion criteria. Reviewers resolved disagreements by consensus or,
when a discrepancy remained, through discussion with a third reviewer.
Data Extraction
Two raters independently extracted all valuable data from the final set of
eligible articles, which included basic information, prevalence, causes, risk
factors (age, gender, New York Heart Association (NYHA) cardiac function
class IV, pulmonary hypertension, diabetes mellitus, chronic obstructive
pulmonary disease (COPD), peripheral vascular disease, emergency sur-
gery, intra-aortic balloon counterpulsation (IABC), cardiopulmonary bypass
(CPB) time, renal disease, aortic crossclamp time, mechanical ventilation
time, reintervention, reintubation), and indexes representing clinical out-
comes (mortality and length of stay in the ICU), to provide a comprehensive
description of VAP after cardiac surgery.
Quality Assessment
The quality of the studies used in this analysis was evaluated using the
Newcastle-Ottawa Scale (NOS).7 The studies were judged based on 3 broad
perspectives: selection (4 items), comparability (1 item), and exposure or
outcome (3 items) by a star rating system with a score ranging from 0 to
9. A high-quality study should achieve 7 stars or more, a medium quality
study between 4 and 6 stars, and a poor-quality study less than 4 stars.
Statistical Analysis
Pooled patient information as well as the incidence and causes of VAP
after cardiac surgery were characterized using descriptive statistics; an
overall meta-analysis was performed to summarize the risk factors and
clinical outcomes. The results were synthesized and analyzed using theThe Journal of Thoracic and CarReviewManager Software (RevMan 5.2; Cochrane Collaboration. Oxford,
United Kingdom). For measurement data, the weighted mean difference
and 95% confidence intervals (CIs) were calculated to compare the
mean difference. For count data, odds ratios (ORs) and 95% CIs were
used. Statistical heterogeneity was assessed using the I2 statistic. When
I2 was greater than 50%, heterogeneity was considered to be present and
we selected the random effect models for the analysis. Otherwise, a fixed
effect model was used. The possibility of publication bias, which can result
from small unpublished studies with negative results, was assessed visually
using a funnel plot for asymmetry.
RESULTS
Search Results and Study Selection
A total of 814 articles were initially identified in the
PubMed, Embase, Cochrane Library, and Web of Knowl-
edge databases or by a manual approach using the key words
as described earlier. After duplicates were removed, 462
potentially relevant articles remained. Based on titles and ab-
stracts, a further 387 articles were subsequently excluded. Of
the 75 remaining articles, there was no appropriate compar-
ison group in 34 articles. Twelve articles were removed
because there was no specific definition for VAP. Patients
enrolled in 8 studies did not all undergo cardiac surgery.
We could not extract a useful index for description of VAP
in 5 articles. In addition, there were 3 review articles, and
the full-length article could not be retrieved for 2 studies.
Finally, 11 articles were included in this systematic review
(Figure 1).8-18 The meta-analysis was based on 9 articles,
excluding 1 descriptive study11 and 1 questionnaire survey.15
Study Characteristics and Quality Assessment
A total of 11 studies including 10,708 patients were
enrolled in our study. Basic information is summarized in
Table 1. Nine articles were included in the meta-analysis;
3 articles were case-control studies and 6 articles were
cohort studies. After evaluated byNOS, 2 articles got 5 stars,
4 articles got 6 stars, and 3 articles got 7 stars (Table E1). No
poor-quality articles were included in our study.
Prevalence
The prevalence of VAP among patients who had
undergone cardiac surgery was described in 9 articles, and
the mean value was 6.37%. The lowest level reported
previously was 2.1% and the highest was 13%. In patients
who had mechanical ventilation for more than 48 hours,
the averaged incidence of VAP was 35.2% (range,
17.9%-53%). A conclusion from 6 articles also found
that an average of 21.27 VAP episodes occurred per 1000
days of mechanical ventilation (range, 13.9-34.5). These
data (Table 2) indicate that the prevalence of VAP after
cardiac surgery is high, especially among those under me-
chanical ventilation for more than 48 hours.
Etiology
Nine papers reported the microorganisms responsible
for VAP (Table 3). Among the gram-positive bacteria,diovascular Surgery c Volume 148, Number 6 3149
FIGURE 1. Flow diagram of the study selection process. VAP, Ventilator-associated pneumonia.
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MStaphylococcus aureus was detected most frequently,
accounting for 20.15% of total pathogens with a standard
deviation of 12.89%. The mean values for methicillin-
sensitive Staphylococcus aureus and methicillin-resistant
Staphylococcus aureus were 13.13% and 14.13%, respec-
tively. Among the gram-negative bacteria, Pseudomonas
aeruginosa was the most important with a mean detectionTABLE 1. Basic characteristics of the studies
Study
Number of patients
VAP Non-VAP
Sheng, 20128 105 1583
Tamayo, 20129 124 1486 68
Roeleveld, 201110 11 114 2
Wojkowska-Mach, 200911 53 2367
Tang, 200912 13 87 0.6
Hortal, 200913 106 1738
Hortal, 200914 20 951
Boaza, 200615 24 296
Pawar, 200316 25 927 59
Bouza, 200317 52 304 64.0
Torres, 199018 78 244 54
MV, Mechanical ventilation; VAP, ventilator-associated pneumonia; CABG, coronary arter
NNISS, National Nosocomial Infection Surveillance System. *Values are represented as t
range); other values are represented as numbers.
3150 The Journal of Thoracic and Cardiovascular Surrate of 23.19%. Some other gram-negative bacteria also
played a significant role in the occurrence of VAP,
including Klebsiella (9.52%  4.77%), Acinetobacter
(10.68%  9.22%), Escherichia coli (10.18%  7.53%),
Stenotrophomonas maltophilia (4.78%  3.47%),
Haemophilus influenza (19.53%  18.22%), Proteus
vulgaris (2.37%  2.29%), and Shewanella oneidensisAge (years)* Gender (male/female)
VAP Non-VAP VAP Non-VAP
54.0  13.5 78/27 869/714
.5  10.0 67.8  10.5 46/78 584/902
.4  4.2 1.3  2.2 7/4 61/53
— — — —
8  0.96 4.14  5.84 7/6 45/42
64.7  12.5 1058/786
64.1  12.2 690/281
— — — —
.7  12.7 56.5  10.7 21/4 818/109
9  11.2 223/113
.5  17.7 55/23 162/82
y bypass grafting; CHD, congenital heart disease; CDC, Centers for Disease Control;
he mean  standard derivation. yValues are represented as the mean (interquartile
gery c December 2014
He et al Perioperative Management(3.8%  4.34%). Some fungi, such as Candida albicans,
were detected (7.2%  6.58%). Several other VAP
pathogens were found. Two additional patients were found
to be infected with Rhinovirus.10 Polymicrobial infections
and even negative cultures were also reported in previous
literature. From the data, it was concluded that VAP after
cardiac surgery is a multifactorial disease, mainly caused
by gram-negative bacteria. Staphylococcus aureus and
Pseudomonas aeruginosa were found to be the 2 major
contributors, at almost half of all pathogens.
Risk Factors
Fifteen potential risk factors (reported in at least 3
studies) are summarized in the present meta-analysis,
divided into 3 categories: preoperative (age, gender,
NYHA cardiac function class IV, pulmonary hypertension,
diabetes mellitus, COPD, peripheral vascular disease, renal
disease), intraoperative (emergency surgery, IABC, CPB
time, aortic crossclamp time), and postoperative (mechani-
cal ventilation time, reintervention, reintubation).
Age. Six studies including 6319 patients indicated there
was no association between age and the occurrence of
VAP after cardiac surgery in children (random effect model;
P ¼ .57; 95% confidence interval [CI], 69.33, 38.14),
adults (fixed effect model; P ¼ .26; 95% CI, 0.73,
2.73). However, VAP was more likely to occur in elderly
people more than 70 years of age (fixed effect model;
P<.01; 95% CI, 2.17, 3.94) (Figure 2, A).TABLE 1. Continued
Duration of MV (days) Mortality Types o
VAP Non-VAP VAP Non-VAP VAP
9.6 (6.1-12)y 0.7 (0.6-0.8)y 27 46 421 valve, 625 CABG, 48 valve þ CAB
25.2  26.2* 1.8  7.2* 61 30 72 valve, 34 CABG, 15 valve þ CABG
1017 valve, 665 CABG, 30 valve þ CA
7.6  3.9* 4.9  5.8* 0 3 —
— — — — —
26.92  8.55* 2.95  0.41* 5 4 12 complex CHD correction surgery, 1
simple CHD correction surgery
46 complex CHD correction surgery, 54
9 (5.7-24)y 1 (1-1)y 48 49 971 valve, 393 CABG, 176 valve þ CA
114 others
9.5 (5-29)y 1 (1-1)y 7 22 267 valve, 528 CABG, 76 valve þ CAB
40 others
— — — — —
6.4  4.8* 0.8  0.3* 4 2 —
3.5  3.6* 0.7  1.2* — — 178 valve, 128 CABG, 22 valve þ CAB
correction surgery, 2 pericardiectom
— — 26 47 —
The Journal of Thoracic and CarGender (male). Six studies including 4797 patients indi-
cated there was no association between gender and the
occurrence of VAP after cardiac surgery (random effect
model; P ¼ .29; 95% CI, 0.82, 1.93) (Figure 2, B).
NYHA cardiac function class IV. Three studies including
3888 patients indicated that VAP was more likely to occur
in patients with NYHA cardiac function class IV after
cardiac surgery (random effect model; P< .01; 95% CI,
1.68, 5.73) (Figure 2, C).
Pulmonary hypertension. Three studies including 3657
patients indicated that VAP was more likely to occur in
patients with pulmonary hypertension (fixed effect model;
P ¼ .01; 95% CI, 1.13, 2.38) (Figure 2, D).
Diabetes mellitus. Four studies including 6094 patients
indicated that there was no association between diabetes
mellitus and the occurrence of VAP after cardiac surgery
(fixed effect model; P ¼ .10; 95% CI, 0.97, 1.53)
(Figure 2, E).
Chronic obstructive pulmonary disease. Five studies
including 6416 patients indicated that VAP was more likely
to occur in patients with COPD (fixed effect model; P<.01;
95% CI, 1.18, 2.01) (Figure 2, F).
Peripheral vascular disease. Three studies including
4425 patients indicated that VAP was more likely to occur
in patients with peripheral vascular disease (random effect
model; P ¼ .01; 95% CI, 1.40, 19.59) (Figure 2, G).
Renal disease. Four studies including 6113 patients indi-
cated that VAP was more likely to occur in patients withf operation
Study type Definition of VAPNon-VAP
G, 116 aorta, 478 others Case-control study American Thoracic
Society
945 valve, 631 CABG,
15 valve þ CABG
Cohort study CDC
BG
— Case-control study CDC
— Descriptive study CDC
34 complex CHD correction surgery,
53 simple CHD correction surgery
Case-control study NNISS
simple CHD correction surgery
BG, 61 heart transplantation, 129 aorta, Cohort study CDC
G, 14 heart transplantation, 46 aorta, Cohort study CDC
— Questionnaire
survey
CDC
— Cohort study Own description
G, 11 heart transplantation, 7 CHD
y, 8 aorta
Cohort study CDC
— Cohort study Own description
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TABLE 2. Prevalence of ventilator-associated pneumonia after
cardiac surgery
Study
VAP in all
patients (%)
VAP in patients
requiring MV
for>48 hours (%)
VAP episodes
per 1000 days
of MV
Sheng, 20128 6.2 53 —
Tamayo, 20129 7.7 — —
Roeleveld, 201110 8.8 — 17.1
Wojkowska-Mach,
200911
2.2 — 18.3
Tang, 200912 13 — 21.6
Hortal, 200913 5.7 45.9 22.2
Hortal, 200914 2.1 17.9 13.9
Boaza, 200615 7.5 — —
Bouza, 200317 7.87 — 34.5
Torres, 199018 — 24 —
Average 6.37 35.2 21.27
VAP, Ventilator-associated pneumonia; MV, mechanical ventilation.
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5.84) (Figure 2, H).
Emergency surgery. Three studies including 4484
patients indicated that VAP was more likely to occur in
patients who underwent emergency surgery (random effect
model; P<.01; 95% CI, 1.99, 10.90) (Figure E1, A).
Intra-aortic balloon counterpulsation. Four studies
including 5455 patients indicated that VAP was more likely
to occur in patients with IABC implantation (random effect
model; P<.01; 95% CI, 3.28, 10.01) (Figure E1, B).
Cardiopulmonary bypass time. Five studies including
5367 patients indicated that prolonged CPB time may
increase the risk for VAP after cardiac surgery (fixed effect
model; P<.01; 95% CI, 19.75, 29.09) (Figure E1, C).
Aortic crossclamp time. Five studies including 5367 pa-
tients indicated that prolonged aortic crossclamp time
may increase the risk for VAP after cardiac surgery (fixed
effect model; P<.01; 95% CI, 8.84, 19.20) (Figure E1, D).
Mechanical ventilation time. Five studies including 3143
patients indicated that prolonged mechanical ventilation
time may increase the risk for VAP after cardiac surgery
(random effect model; P< .01; 95% CI, 70.98, 218.21)
(Figure E2, A).
Reintervention. Six studies including 7190 patients
indicated that postoperative reintervention was an impor-
tant factor causing VAP (random effect model; P< .01;
95% CI, 1.80, 6.31) (Figure E2, B).
Reintubation. Four studies including 4210 patients
indicated that postoperative reintubation was an important
factor causing VAP (random effect model; P< .01; 95%
CI, 5.15, 68.77) (Figure E2, C).
These results demonstrated that NYHA cardiac function
class IV, pulmonary hypertension, COPD, peripheral
vascular disease, renal disease, emergency surgery, IABC,
CPB time, aortic crossclamp time, mechanical ventilation
time, reintervention and reintubation were risk factors for3152 The Journal of Thoracic and Cardiovascular SurVAP after cardiac surgery, whereas gender and diabetes
mellitus were not.
Clinical Outcomes
Eight studies including 7612 patients indicated that mor-
tality was increased significantly in patients infected with
VAP (random effect model; P<.01; 95% CI, 5.81, 39.68)
(Figure E3, A). Length of stay in the ICU was also affected
by VAP according to data extracted from 5 studies involving
4475 patients (random effect model; P<.01; 95% CI, 6.65,
39.91) (Figure E3, B). These results suggest that VAP after
cardiac surgery is closely related to a poor prognosis.
Publication Bias
To determine publication bias in the present study, we
drew funnel plots as the evaluation criteria. The results
showed that symmetry was good in the analysis of
pulmonary hypertension, diabetes mellitus, COPD, CPB
time and aortic crossclamp time; some publication bias
existed in other analyses (Figure E4).
DISCUSSION
VAP is the most frequently encountered nosocomial
infection in all ICUs. Great challenges still remain in the
diagnosis of VAP, because of its various clinical manifesta-
tions and pathogens.19 The clinical criteria for VAP are
commonly based on the guidelines from the Centers for
Disease Control and Prevention. It is defined as the presence
of new and/or progressive pulmonary infiltrates on a chest
radiograph, plus 2 or more of the following: fever
(38.5C) or hypothermia (<36C), leukocytosis
(12 3 109/L), purulent tracheobronchial secretions, or a
reduction in PaO2/FiO2 (partial pressure of arterial oxygen/
fraction of inspired oxygen) of 15% or more in the previous
48 hours,20 Bacteriologic cultures, serum biomarkers, and
some other techniques are also useful for diagnosing VAP,
however, their contributions are considered limited.21
Heart surgery, especially CPB, often triggers an
abnormal systemic inflammatory reaction and releases a se-
ries of proinflammatory mediators.22,23 Combined with
other factors, such as anesthesia and hypothermia,
impaired lung function is common in this subpopulation,
leading to the need for long-term mechanical ventilation.24
Previous studies have suggested that prolonged weaning
may disrupt the normal barrier in the respiratory tract,
thus increasing the risk for infections and leading to high
mortality.25 As a result, a high prevalence of VAP can be ex-
pected in patients who have undergone cardiac surgery,
which is verified in our study.
A good prognosis is usually attributable to the initial
treatment of VAP with an appropriate antimicrobial
regimen.26 Some previous studies found that early adminis-
tration of antibiotics could prevent undue prolongation of
mechanical ventilation and reduce mortality in patientsgery c December 2014
TABLE 3. Detection rate of pathogens in patients infected with ventilator-associated pneumonia after cardiac surgery (%)
Pathogen
Sheng,
20128
Tamayo,
20129
Roeleveld,
201110
Wojkowska-Mach,
200911
Tang,
200912
Hortal,
200913
Pawar,
200316
Bouza,
200317
Torres,
199018 Mean ± SD
Gram-positive
Staphylococcus aureus 15.7 44.3 18.2 4.2 25 27.1 9.5 17.2 2.6 20.15  12.89
MSSA — 20.1 — — 10 9.3 — — — 13.13  6.04
MRSA — 9.6 — — 15 17.8 — — — 14.13  4.17
Gram-negative
Pseudomonas aeruginosa 24.2 20.9 9.1 10.4 45 28.6 52.3 17.2 6.4 23.19  15.95
Klebsiella 13.6 7.3 — 16.7 5 5 9.5 — — 9.52  4.77
Acinetobacter 10.6 28.2 — 6.3 — 2.8 4.7 — 11.5 10.68  9.22
Escherichia coli 8.1 2.4 — 12.5 5 9.3 23.8 — — 10.18  7.53
Stenotrophomonas
maltophilia
6.1 0.8 — — 10 3.6 — 3.4 — 4.78  3.47
Haemophilus influenzae — 12.1 45.5 — — 17.1 — 3.4 — 19.53  18.22
Proteus vulgaris — 0.8 — — — 5 — — 1.3 2.37  2.29
Shewanella oneidensis — 1.6 — — — 2 — 10.3 1.3 3.8  4.34
Fungus
Candida albicans 2 — — 14.6 5 — — — — 7.2  6.58
SD, Standard deviation; MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus.
He et al Perioperative Managementwith VAP, so empirical therapy is essential within 24
hours.27,28 For patients who have undergone cardiac
surgery, our study revealed that gram-negative bacteria,
particularly Pseudomonas aeruginosa, are the majorFIGURE 2. Meta-analysis of preoperative risk factors. A, Age; B, gender; C,
mellitus; F, chronic obstructive pulmonary disease; G, peripheral vascular dise
deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel
The Journal of Thoracic and Carcause of VAP, so we recommend third- or fourth-
generation cephalosporins as the preferred antimicrobial
program (eg, cefoperazone, ceftazidime, or cefepime).
Other antibiotics against this type of pathogen can also beNYHA cardiac function class IV; D, pulmonary hypertension; E, diabetes
ase; H, renal disease. VAP, Ventilator-associated pneumonia; SD, standard
; COPD, chronic obstructive pulmonary disease.
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ciated with better microbiological and clinical outcomes,29
despite high cost, greater toxicity, and potential drug
resistance.30 However, this was recently refuted by a
meta-analysis of randomized trials, which proved that there
was no significant difference between monotherapy and
combination therapy with regard to efficacy and mortality,
and a superior empirical regimen was still not evident.31
The microbial pathogens are not the same in different
settings or different regions, thus experience from the local
institution seems especially important. Once the results of
bacteriologic cultures are available, the antibiotics should
be adjusted to sensitive drugs as quickly as possible.
In addition to empirical therapy, preventive measures
aiming at the risk factors are also significant. Our study
found 6 valuable preoperative risk factors. Before surgery,
we advocate aggressive therapies for existing diseases to
reduce the risks for VAP; for example, improve cardiac
and renal function, alleviate pulmonary hypertension, treat
COPD or peripheral vascular diseases. However, not all pre-
operative diseases can be cured efficiently, and some factors
such as age or gender are immutable. So making a quantita-
tive index for patients seems a promising method of preven-
tion. We can grade patients based on this evidence and
provide solutions for each aspect. Hortal and colleagues14
have already made some attempt to do this. They developed
a day 0 score to identify the population at risk for VAP with
variables available before surgery; a day 3 score was devel-
oped for patients who remained ventilated for more than 48
hours. They were able to identify 93% of patients who
would develop VAP with a specificity of 40%. However,
some researchers pointed that this score was developed
based on a small numbers of patients and therefore of
limited use.32 The results of the present study or other
studies should be considered when setting criteria, and the
practicalities must also be validated by further research.
During surgery, minimizing the CPB time and aortic clamp-
ing are key to preventing VAP. In addition, there should be
more focus on patients undergoing emergency surgery or
undergoing IABC implantation. Favorable postoperative
care and nursing are believed to reduce mechanical ventila-
tion time and avoid intubation or reinvention, which could
reduce the risk for VAP.33
There are some limitations of this study. The patients
included in our study all underwent heart surgery. It is re-
ported that the clinical characteristics of patients of
different ages are not the same.34 Geographic location is
also a factor that affects the results. Therefore, our study
should be further analyzed in different subgroups classified
by age, region, or other factors. In addition, the number of
eligible articles seems small. Several aspects that were
reported and believed to be responsible for VAP in the
literature were not described in our study, just because the
results could not be merged from a sufficient number of3154 The Journal of Thoracic and Cardiovascular Surstudies. This is also the reason why publication bias is still
present in some analysis. Nursing is also important for the
prevention and treatment of VAP after cardiac surgery, but
we failed to investigate its effect; this must be studied in
future research.
CONCLUSIONS
In the present study, we selected all eligible studies on
VAP after cardiac surgery, demonstrating that patients
who have undergone heart operation are commonly infected
with VAP. Gram-negative bacteria account for a large
proportion of the pathogens, among which Pseudomonas
aeruginosa is a major contributor. We also found that
VAP is closely related to high mortality and long ICU
stay. NYHA cardiac function class IV, pulmonary hyperten-
sion, COPD, peripheral vascular disease, renal disease,
emergency surgery, IABC, CPB time, aortic crossclamp
time, mechanical ventilation time, reintervention, and
reintubation are proven risk factors for infection, providing
potential targets for the prevention and treatment of VAP
after cardiac surgery.
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MVentilator-associated pneumonia (VAP) is the most com-
mon nosocomial infection that occurs after heart surgery
and is associated with significant morbidity and mortality.
He and colleagues1 performed a contemporary meta-
analysis summarizing the prevalence, cause, risk factors,and outcome of VAP after cardiac surgery. Results showed
that the prevalence of VAP after cardiac surgery was 6.37%,
and that the risk of mortality increased 15-fold in patients
with VAP. Several important risk factors associated with
VAP were further identified. This study highlights the scope
and significance of VAP after cardiac surgery and should
redirect attention to basic strategies for VAP prevention.
CLINICAL SUMMARY
VAP is the most common nosocomial infection that oc-
curs after heart surgery and is associated with significant
morbidity and mortality.2 He and colleagues1 performed a
contemporary meta-analysis and literature review of the
prevalence, cause, risk factors, and outcome of VAP after
cardiac surgery, described in the current issue of the Jour-
nal. The study is of high-quality and sound statistical
design, and the data effectively summarize the benchmark
rates of VAP, responsible pathogens, risk factors for VAP,
and impact of VAP on patient outcomes.diovascular Surgery c Volume 148, Number 6 3155
FIGURE E1. Meta-analysis of intraoperative risk factors. A, Emergency surgery; B, intra-aortic balloon counterpulsation; C, cardiopulmonary bypass
time; D, aortic crossclamp time. VAP, Ventilator-associated pneumonia;M-H, Mantel-Haenszel;CI, confidence interval; IABC, intra-aortic balloon counter-
pulsation; CPB, cardiopulmonary bypass; SD, standard deviation; IV, inverse variance.
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FIGURE E2. Meta-analysis of postoperative risk factors. A, Mechanical ventilation time; B reintervention; C, reintubation. VAP, Ventilator-associated
pneumonia; SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.
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FIGURE E3. Meta-analysis of clinical outcomes. A, Mortality; B, length of stay in the intensive care unit. VAP, Ventilator-associated pneumonia;
M-H, Mantel-Haenszel; CI, confidence interval; ICU, intensive care unit; SD, standard deviation; IV, inverse variance.
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FIGURE E4. Funnel plots of each analysis. A, Gender; B, New York Heart Association cardiac function class IV; C, pulmonary hypertension; D, diabetes
mellitus; E, chronic obstructive pulmonary disease; F, peripheral vascular disease; G, renal disease; H, emergency surgery; I, intra-aortic balloon
counterpulsation; J, cardiopulmonary bypass time; K, aortic crossclamp time; L, mechanical ventilation time; M, reintervention; N, reintubation;
O, mortality; P, length of stay in the intensive care unit. SE, Standard error; OR, odds ratio; MD, mean difference.
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TABLE E1. Quality assessment of the studies using the Newcastle-Ottawa quality scale
Study
Selection Comparability Exposure
Total
scores
Is case
definition
adequate?
Representativeness
of cases
Selection of
controls
Definition
of controls
Comparability
on the basis
of designs
or analysis
Ascertainment
of exposure
Same
ascertainment
method for
cases and
controls
Nonresponse
rate
Case-control studies
Sheng, 20128 + + + + + 5
Roeleveld, 201110 + + + + + 5
Tang, 200912 + + + + + + 6
Selection Comparability Outcome
Total
scores
Representativeness
of exposed cohort
Selection
of the
nonexposed
cohort
Ascertainment
of exposure
Demonstration
that outcome
was not
present at
start of study
Comparability
on the basis
of design
or analysis
Assessment
of outcome
Was
follow-up
long
enough for
outcomes
to occur?
Adequacy
of follow-up
of cohorts
Cohort studies
Tamayo, 20129 + + + + + + + 7
Hortal, 200913 + + + + + + + 7
Hortal, 200914 + + + + + + 6
Pawar, 200316 + + + + + + 7
Bouza, 200317 + + + + + + 6
Torres, 199018 + + + + + + 6
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